DARE News and Press, Dare Bioscience Inc. From 08/10/23

2023-08-10 19:54:04 ET Daré Bioscience, Inc. (DARE) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Commercial Officer Lisa Walters-Hoffert - ...

2023-08-10 11:02:27 ET Dare Bioscience press release ( NASDAQ: DARE ): Q2 GAAP EPS of -$0.10 misses by $0.01 . Cash and cash equivalents: $13.3 million at June 30, 2023. For further details see: Dare Bioscience GAAP EPS of -$0.10 misses by $0.01

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)) : XACIATO™ First Commercial Sale Ovaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study &#...

2023-08-09 17:35:07 ET Dare Bioscience ( NASDAQ: DARE ) is scheduled to announce Q2 earnings results on Thursday, August 10th, after market close. The consensus EPS Estimate is -$0.09 vs $0.00 in 2Q22 and the consensus Revenue Estimate is $0.9M (-91.0% Y/Y). Over ...

DARE-HRT1 Demonstrated Preliminary Treatment Efficacy for Both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM) The North American Menopause Society (NAMS) Guidance on Hormone Therapy States that Dosing Estrogen and Progestogen in Combination May Offer Important ...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results f...

Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and Treatment of Idiopathic Preterm Birth Currently no FDA-Approved Product for the Treatment of Preterm Birth SAN DIEGO, July 31, 2023 (G...

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devi...

Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire Seen in the Sildenafil Cream Group Persisted through End of Study There are no FDA-approved treatments for femal...

Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in wome...